Published in Cancer Res on July 01, 2007
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence. PLoS One (2016) 1.40
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
Vitiligo--part 1. An Bras Dermatol (2014) 0.96
In vivo Treg suppression assays. Methods Mol Biol (2011) 0.95
Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93
BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res (2014) 0.93
Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res (2008) 0.92
The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. Oncoimmunology (2013) 0.81
Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcoma. PLoS One (2013) 0.80
Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80
Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors. PLoS One (2012) 0.76
Resident memory T cells in the skin mediate durable immunity to melanoma. Sci Immunol (2017) 0.75
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol (2003) 15.51
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 10.22
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Molecular and functional profiling of memory CD8 T cell differentiation. Cell (2002) 8.06
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol (2004) 6.80
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Naive and memory CD4+ T cell survival controlled by clonal abundance. Science (2006) 4.67
Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A (2004) 4.56
CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med (2003) 4.56
CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev (2006) 4.49
Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol (2006) 4.26
Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med (2001) 4.17
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 3.81
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Understanding the generation and function of memory T cell subsets. Curr Opin Immunol (2005) 3.22
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
CD8+ T cell contraction is controlled by early inflammation. Nat Immunol (2004) 3.13
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol (1987) 2.51
Differential contributions of central and effector memory T cells to recall responses. J Exp Med (2005) 2.40
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med (2002) 2.20
Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res (2004) 2.18
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (2005) 2.01
Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med (2003) 1.68
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66
Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol (2003) 1.40
Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol (2006) 1.36
Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol (2000) 1.29
Effect of anti-CD4 on CD4 subsets. I. Anti-CD4 preferentially deletes resting, naive CD4 cells and spares activated CD4 cells. J Immunol (1994) 1.27
Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev (2002) 1.14
Cutting edge: regulation of CD8+ T cell effector population size. J Immunol (2004) 1.09
Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med (1984) 1.04
Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res (2002) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Effect of chronic viral infection on epitope selection, cytokine production, and surface phenotype of CD8 T cells and the role of IFN-gamma receptor in immune regulation. J Immunol (2004) 1.01
Immunological consequences of tumor excision: from active immunity to immunological memory. Int J Cancer (1986) 0.96
A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res (2005) 0.93
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev (2009) 3.56
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol (2004) 3.15
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
CD4+ T cell regulation of CD25 expression controls development of short-lived effector CD8+ T cells in primary and secondary responses. Proc Natl Acad Sci U S A (2009) 2.01
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev (2004) 1.58
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly-6C(neg) bone marrow precursors in a mouse model of asthma. Blood (2002) 1.36
Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection. J Virol (2006) 1.36
Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol (2004) 1.35
Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J Immunol (2009) 1.34
The immortality of humoral immunity. Immunol Rev (2010) 1.33
Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J Immunol (2004) 1.30
IL-15-independent proliferative renewal of memory CD8+ T cells in latent gammaherpesvirus infection. J Immunol (2004) 1.30
Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol (2011) 1.29
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol (2008) 1.27
The distinctive germinal center phase of IgE+ B lymphocytes limits their contribution to the classical memory response. J Exp Med (2013) 1.26
Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol (2008) 1.22
Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol (2006) 1.21
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene (2003) 1.16
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol (2012) 1.16
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Murid herpesvirus 4 strain 68 M2 protein is a B-cell-associated antigen important for latency but not lymphocytosis. J Virol (2003) 1.14
CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. J Virol (2006) 1.11
Airway eosinophils accumulate in the mediastinal lymph nodes but lack antigen-presenting potential for naive T cells. J Immunol (2003) 1.10
A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. Cancer Res (2012) 1.09
CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Mol Cancer Res (2009) 1.09
Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res (2003) 1.07
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol (2011) 1.07
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med (2012) 1.06
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin Cancer Res (2006) 1.04
Cutting edge: IL-2 immune complexes as a therapy for persistent virus infection. J Immunol (2009) 1.04
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus. J Immunol (2011) 1.02
CD8+ T cell dysfunction and increase in murine gammaherpesvirus latent viral burden in the absence of 4-1BB ligand. J Immunol (2007) 1.01
Immune responses against persistent viral infections: possible avenues for immunotherapeutic interventions. Crit Rev Immunol (2008) 0.99
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
MicroRNA miR-155 affects antiviral effector and effector Memory CD8 T cell differentiation. J Virol (2012) 0.93
Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93
Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res (2008) 0.92
Strain-dependent requirement for IFN-γ for respiratory control and immunotherapy in murine gammaherpesvirus infection. Viral Immunol (2011) 0.90
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Critical role for all-trans retinoic acid for optimal effector and effector memory CD8 T cell differentiation. J Immunol (2013) 0.88
Murine gammaherpesvirus 68 LANA acts on terminal repeat DNA to mediate episome persistence. J Virol (2012) 0.87
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines Cell Mol Ther (2002) 0.87
Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer. Lung (2013) 0.86
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine. PLoS One (2012) 0.86
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res (2014) 0.85
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb) (2013) 0.84
Immune escape of γ-herpesviruses from adaptive immunity. Rev Med Virol (2014) 0.84
Differential requirements for CD80/86-CD28 costimulation in primary and memory CD4 T cell responses to vaccinia virus. Cell Immunol (2010) 0.80
Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80
Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect. J Immunol (2013) 0.79
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
CD4 and CD8 T cells directly recognize murine gammaherpesvirus 68-immortalized cells and prevent tumor outgrowth. J Virol (2013) 0.79
T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics. J Virol (2004) 0.78
CD4(+) T-cell dependence of primary CD8(+) T-cell response against vaccinia virus depends upon route of infection and viral dose. Cell Mol Immunol (2014) 0.75